1. Home
  2. FEMY vs QNRX Comparison

FEMY vs QNRX Comparison

Compare FEMY & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

N/A

Current Price

$1.40

Market Cap

11.5M

Sector

Health Care

ML Signal

N/A

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

N/A

Current Price

$4.21

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FEMY
QNRX
Founded
2004
2018
Country
United States
United States
Employees
54
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
9.2M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
FEMY
QNRX
Price
$1.40
$4.21
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$14.33
★ $20.38
AVG Volume (30 Days)
★ 103.5K
22.7K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 44.71
N/A
EPS
N/A
★ N/A
Revenue
★ $2,293,313.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$328.45
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 40.77
N/A
52 Week Low
$0.29
$3.25
52 Week High
$6.29
$23.50

Technical Indicators

Market Signals
Indicator
FEMY
QNRX
Relative Strength Index (RSI) 28.99 43.71
Support Level $0.37 $4.03
Resistance Level $3.21 $4.50
Average True Range (ATR) 0.17 0.24
MACD -0.00 0.09
Stochastic Oscillator 17.65 69.57

Price Performance

Historical Comparison
FEMY
QNRX

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: